Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTaghi ManshouriCLChristopher LyADAndrew Dunbar

Discussion

Loading...

Member takes

Overview

Quantitative profiling shows reduced fibrocytes and mesenchymal stromal cells in spleen of myelofibrosis, suggesting implications for JAK inhibitor therapy.

Key Points

  • This research explores the abundance of fibrocytes and mesenchymal stromal cells in myelofibrosis spleens, focusing on their clinical correlations.
  • Analyzed spleen samples from 31 myelofibrosis patients and matched bone marrow samples for fibrocytes and MSCs.
  • Utilized multiplexed imaging and targeted mutational profiling on spleen samples.
  • Determined reticulin and collagen fiber density using immunofluorescence assays.
  • Fibrocyte and MSC frequencies were significantly lower in myelofibrosis spleens compared to healthy controls.
  • JAK2V617F variant allele fraction was higher in bone marrow than in spleen for paired samples.
  • Fibrocytes showed inverse correlation in bone marrow with reticulin fibrosis.

Cite This Study

Manshouri et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e59dhttps://doi.org/10.1182/blood-2025-5542
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Transcriptomic analysis of CD34⁺ cells in myelofibrosis highlights their role in extracellular matrix dysregulation and marrow fibrosis2025 · 1 citations
  2. 2Sequential Analysis of Murine Myelofibrosis Models Using a Novel Deep Learning‐Based Fibrosis Quantitative Method2026 · 1 citations
  3. 3A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications2026
  4. 4Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study2026
  5. 5Advanced myelofibrosis is marked by loss of NKG2D and DNAM-1 NK activating signaling and increased TIM-3 T CD8 exhaustion2025